


Please type a plus sign (+) inside this box → ☐



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/308,080
Filing Date	October 28, 1999
First Named Inventor	Frank Gonzalez
Group Art Unit	1652
Examiner Name	Steadman, D
Attorney Docket Number	015280-271100US

RECEIVED
APR 18 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS	AC	Gonzalez, F., et al., "Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency," <u>TIPS</u> , 16:325-327 (1995).	
	AD	Hiroshi Y., et al. "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-flourouracil toxicity and congenital thymine uraciluria," <u>J. Biol. Chem.</u> , 269:23192-23196 (1994).	
	AE	JOURNAL BIOLOGICAL CHEMISTRY, vol. 264, no. 20, July 1990, pages 12067-74, XP002032866 KUIVANIEMI, H., ET AL: "Identical G to a mutations in three different introns of the type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers-Danlos Syndrome IV," see abstract	
	AF	Meisma, R., et al., "Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea," <u>DNA & Cell. Biol.</u> , 14(1):1-6 (1995).	
	AG	NUCLEIC ACIDS RESEARCH, vol. 15 no. 14, 1987, pages 5613-28, XP002032865 MARVIT, J. ET AL: "GT to AT transition at a splice donor site causes skipping of the preceeding exon in phenylketonuria" see abstract	
	AH	SINGAPORE JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 26, no. 3, November 1995, pages 176-86, XP000600337 ROY ET AL: "molecular scanning of human diseases" see the whole document.	
	AI	Vreken, P., et al., "A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency," <u>J. Inherit. Metab. Dis.</u> , 19(5):645-54 (1996).	
DS	AJ	Wei, X., et al. "Molecular Basis of the Human Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluorouracil Toxicity," <u>J. Clin. Invest.</u> , 98(3):610-615 (1996).	


Examiner Signature	<i>DS</i>	Date Considered	6/30/02
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9039543 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

Complete if Known

Application Number: 09/308,080
 Filing Date: October 28, 1999
 First Named Inventor: Frank Gonzalez
 Group Art Unit: 1652
 Examiner Name: Steadman, D
 Attorney Docket Number: 015280-271100US

RECEIVED
 APR 18 2002
 TECH CENTER 1000:2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
NS	AA	5,856,454		Gonzalez et al.	01/05/1999	536 / 23.1

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DJS	AB		WO 97/35034		Gonzalez et al.	09/25/1997		

COPY OF PAPERS
 ORIGINALLY FILED

Examiner Signature		Date Considered	6/30/02
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9039543 v1